ライフサイエンスコーパス: mSv

1 p than in the functional-testing group (10.0 mSv vs. 11.3 mSv), but 32.6% of the patients in the func

2 sure was higher in the CTA group (mean, 12.0 mSv vs. 10.1 mSv; P<0.001).

3 SMA I&T resulted in an effective dose of 3.0 mSv.

4 within 5% of the reference standard (at 5.0 mSv) was marked as the optimal setting.

5 same protocol at a lower total dose (0.5-5.0 mSv, with stepped doses of 0.5 mSv).

6 ination had an average effective dose of 5.0 mSv.

7 -MBq administration of (68)Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD.

8 fective dose was reduced to 0.015 +/- 0.0010 mSv/MBq.

9 The mean effective dose was 0.026 +/- 0.0012 mSv/MBq.

10 The effective dose was 0.0326 +/- 0.0018 mSv/MBq.

11 +/- 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

12 en, 0.022 +/- 0.002; women, 0.027 +/- 0.002) mSv/MBq.

13 )Ga-labeled tracers, such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly b

14 ses were 0.009 +/- 0.002 and 0.010 +/- 0.003 mSv/MBq for injected protein masses of 500 and 1,000 mug

15 Total effective dose was 0.030 +/- 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

16 whole-body effective dose estimate of 0.003 mSv/MBq was observed.

17 ffective dose was 0.0258 mSv/MBq (SD, 0.0034 mSv/MBq).

18 oms were 0.013 +/- 0.004 and 0.014 +/- 0.004 mSv/MBq, respectively, depending on the voiding schedule

19 l subjects (mean +/- SD) was 0.029 +/- 0.004 mSv/MBq.

20 ry with an effective dose estimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-

21 .012 mSv [95% CI confidence interval : 0.005 mSv, 0.031 mSv] for adults).

22 /MBq with the RADAR manual method and 0.0052 mSv/MBq with OLINDA/EXM.

23 average radiation effective dose was 0.0055 mSv/MBq with the RADAR manual method and 0.0052 mSv/MBq

24 .012 mSv [95% CI confidence interval : 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confi

25 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

26 dose equivalent in millirems (1 mrem = 0.01 mSv) was recorded from personal dosimeters worn on labor

27 ion group (4.2 +/- 5.3 mSv vs. 0.01 +/- 0.01 mSv, p = 0.036).

28 ry CTA was calculated as 1.11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for meth

29 an estimated human absorbed dose of 2.20E-01 mSv/MBq.

30 at data, the human effective dose was 0.0105 mSv/MBq.

31 The effective dose equivalent was 0.0106 mSv/MBq (0.0392 rem/mCi).

32 d salivary glands (parotids, 0.031 +/- 0.011 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

33 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confidence interval : 0.005 mSv, 0.031 mSv]

34 for conventional radiography (median: 0.012 mSv [95% CI confidence interval : 0.006 mSv, 0.022 mSv]

35 e bladder dose was reduced to 0.10 +/- 0.012 mSv/MBq, and the effective dose was reduced to 0.015 +/-

36 , and the effective dose was 0.023 +/- 0.012 mSv/MBq.

37 of A33 directly labeled with (89)Zr (0.0124 mSv/MBq vs. 0.4162 mSv/MBq, respectively).

38 ith an effective dose of approximately 0.014 mSv/MBq.

39 The calculated effective dose was 0.0141 mSv/MBq when using a 3.5-h voiding interval.

40 spectively, and the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/m

41 The effective dose was 0.015 mSv/MBq, leading to a radiation burden of 3 mSv when the

42 rgans received doses between 0.008 and 0.015 mSv/MBq, with an effective dose of approximately 0.014 m

43 effective doses were 0.012 mGy/MBq and 0.016 mSv/MBq, respectively.

44 The effective dose was estimated to be 0.017 mSv/MBq.

45 to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

46 sed the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marr

47 cents than younger children (0.011 and 0.019 mSv/MBq, respectively; P < 0.0001).

48 5.26E-02 mSv/MBq), and gallbladder (4.05E-02 mSv/MBq).

49 The mean effective dose was 2.07E-02 mSv/MBq.

50 The mean effective dose was 1.02 mSv +/- 0.51.

51 e liver (6.02E-02mSv/MBq), kidneys (5.26E-02 mSv/MBq), and gallbladder (4.05E-02 mSv/MBq).

52 lated effective dose was 2.4E-02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activ

53 An equivalent dose was calculated as 9.6E-02 mSv/MBq for [(55)Co]Co-DOTATATE.

54 se, was the urinary bladder wall at 7.96E-02 mSv/MBq.

55 The effective dose was 0.021 mSv/MBq for males and 0.027 mSv/MBq for females, support

56 ure (effective dose) was approximately 0.021 mSv/MBq.

57 d on extrapolation of mouse data, was 0.0218 mSv/MBq, which would yield a radiation dose of 4 mSv to

58 The mean effective dose was 0.022 mSv/MBq (range, 0.020-0.024 mSv/MBq).

59 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary glands (parotids, 0.031 +/- 0.011

60 5% CI confidence interval : 0.006 mSv, 0.022 mSv] for children and 0.012 mSv [95% CI confidence inter

61 ation effective dose was approximately 0.023 mSv/MBq.

62 , the average total effective dose was 0.023 mSv/MBq.

63 e dose was 0.022 mSv/MBq (range, 0.020-0.024 mSv/MBq).

64 NI-659 effective dose was estimated at 0.024 mSv/MBq.

65 The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi).

66 The effective dose was 0.0258 mSv/MBq (SD, 0.0034 mSv/MBq).

67 e dose was 0.021 mSv/MBq for males and 0.027 mSv/MBq for females, supporting the feasibility of using

68 E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq).

69 E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04mSv/MBq).

70 tetrahydrouridine was 2.12E-02 +/- 4.15E-03 mSv/MBq.

71 sinus rhythm, with a mean difference of 4.03 mSv (95% CI: 0.97, 7.1; P = .01).

72 effective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red

73 ective doses were the bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red

74 erage effective total-body dose was 7.80E-03 mSv/MBq.

75 erage effective total body dose was 7.80E-03 mSv/MBq.

76 .011 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

77 5% CI confidence interval : 0.005 mSv, 0.031 mSv] for adults).

78 e interval [ CI confidence interval ]: 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confide

79 testines were 0.082, 0.043, 0.042, and 0.035 mSv/MBq, respectively.

80 The estimated effective dose was 0.035 mSv/MBq.

81 dose for the investigative protocol was 0.04 mSv (95% confidence interval [ CI confidence interval ]:

82 e (+/- standard deviation) was 0.16 +/- 0.04 mSv for the 32-MDCT and 1.25 +/- 0.30 mSv for the 16-MDC

83 ith ultralow doses of radiation (0.16+/-0.04 mSv).

84 0.05 mSv (95% CI confidence interval : 0.04 mSv, 0.08 mSv) for adults.

85 (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq).

86 ffective dose of (18)F-PF-06684511 was 0.043 mSv/MBq for humans.

87 The effective dose was 0.043 mSv/MBq, resulting in an average of 4.6 mSv per patient.

88 f interest were the bladder (0.102 +/- 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

89 : 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confidence interval : 0.04 mSv, 0.08 mSv) fo

90 0 MBq for 1-y-old children and 0.59 +/- 0.05 mSv for an injected dose of 30 MBq in 5-y-old children.

91 The mean effective dose was 0.051 mSv/MBq.

92 adder wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq).

93 aled a mean effective dose of 0.029 +/- 0.06 mSv/MBq, with the highest organ dose to the pancreas (0.

94 dose for adults was very low (0.71 +/- 0.07 mSv for a standard injected dose of 100 MBq).

95 h an average effective dose of 0.54 +/- 0.07 mSv/MBq.

96 rbed doses were the thyroid (0.135 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivar

97 (95% CI confidence interval : 0.04 mSv, 0.08 mSv) for adults.

98 The effective dose was, 2.05, 1.8, 1.08 mSv for brain, abdomen and chest respectively.

99 r two dual-phase cone-beam CT scans was 3.08 mSv.

100 effective whole-body dose was 0.61 +/- 0.09 mSv.MBq(-1).

101 organ dose to the pancreas (0.274 +/- 0.099 mSv/MBq).

102 .5 mSv for one PET/CT examination versus 0.1 mSv for one chest radiographic examination.

103 ded to an effective dose of 0.22 mSv and 0.1 mSv.

104 r the 4.8-h interval, reduced to 8.3 +/- 1.1 mSv for the 1-h interval.

105 n an approximate effective dose of 8.4+/-1.1 mSv.

106 er in the CTA group (mean, 12.0 mSv vs. 10.1 mSv; P<0.001).

107 of (68)Ga-DOTATATE and (68)Ga-DOTATOC is 2.1 mSv for both tracers.

108 was higher compared to ED(NCI) (9.8 +/- 2.1 mSv) and ED(MC) (11.6 +/- 1.5 mSv).

109 e average effective dose coefficient was 5.1 mSv.

110 ose of staff wearing two badges (median, 7.1 mSv; interquartile range, 4.6-11.2 mSv; n = 1449) (P = .

111 Effective doses were above 1 mSv y(-1) in the CEZ, but much lower in the rest of Euro

112 lent prognosis, a radiation dose averaging 1 mSv, and a test duration of less than 2 h.

113 high quality images with doses as low as <1 mSv in selected patients who have low heart rates with a

114 those procedures with an effective dose </=1 mSv.

115 e resulted in a maternal effective dose of 1 mSv and an embryo/fetal dose of 0.05 mGy.

116 ngiography examinations (21.5%), less than 1 mSv for 58 (54.2%), and less than 4 mSv for 103 (96.3%).

117 esulting in an effective dose of less than 1 mSv for the PET examination.

118 from the FDNPP radionuclides and below the 1 mSv a(-1) benchmark for public exposure.

119 ll Islands (RMI) governments (100 mrem/y = 1 mSv/y).

120 per unit exposure (0.04% versus 0.02% per 1-mSv effective dose for females versus males, respectivel

121 uided lumbar facet joint injections was 0.10 mSv +/- 0.11, compared with 0.33 mSv +/- 0.13 for CT-gui

122 [ CI confidence interval ]: 0.034 mSv, 0.10 mSv) for children and 0.05 mSv (95% CI confidence interv

123 and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv

124 estimates for LDIR exposure (OR, 1.10 per 10 mSv; 95% CI, 1.05-1.15) with a possible dose-related res

125 no strong relationship is apparent below 100 mSv, the doses used in diagnostic imaging.

126 k associated with radiation doses below ~100 mSv is lacking; however, concerns about ionizing radiati

127 This dose decreased to 0.77 +/- 0.11 mSv/20 MBq for 1-y-old children and 0.59 +/- 0.05 mSv fo

128 dose for coronary CTA was calculated as 1.11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.8

129 , 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv)

130 (0.1479 mSv), and the parotid glands (0.1137 mSv/MBq).

131 ted radiation dose exposure of 0.29 +/- 0.12 mSv (range 0.16 to 0.53 mSv), yielding 96.9% (436 of 450

132 : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confidence interval : 0.57 mSv, 3.15 mSv] fo

133 NPP and ambient radionuclides, of which 0.13 mSv a(-1) (14%) was solely from the FDNPP radionuclides

134 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv

135 effective RE than patients without HCC, 137 mSv (IQR: 87,259) versus 32 mSv (IQR: 13,57), respective

136 2 mSv/MBq), the submandibular glands (0.1479 mSv), and the parotid glands (0.1137 mSv/MBq).

137 BY-025 yielded a mean effective dose of 0.15 mSv/MBq and was safe, well tolerated, and without drug-r

138 [95% CI confidence interval : 0.57 mSv, 3.15 mSv] for adults) and of the same order of magnitude as t

139 3 mSv/y, and added exposures of less than 15 mSv are considered low risk for carcinogenesis.

140 R, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mS

141 ne (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq).

142 , 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

143 renals (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibular glands (0.1479 mSv), and the

144 sments (mean equivalent dose to marrow, 0.18 mSv/MBq).

145 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR,

146 e dose from incorporated (137)Cs of about 18 mSv.

147 , 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and ab

148 ered radioactivity were the adrenals (0.1835 mSv/MBq), the kidneys (0.1722 mSv/MBq), the submandibula

149 (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and small intestine (0.17 mSv/MBq).

150 land of Rongelap (mean = 19.8 mrem/y = 0.198 mSv/y), and relatively high gamma radiation on the islan

151 ed activity of (18)F-FAPI-74 was 1.4 +/- 0.2 mSv, and for (68)Ga-FAPI-74 it was 1.6 mSv.

152 t (DLP) was 746 mGy cm (effective dose, 11.2 mSv), with a range of 307-1497 mGy cm (effective dose, 4

153 dian, 7.1 mSv; interquartile range, 4.6-11.2 mSv; n = 1449) (P = .18), suggesting a similar radiation

154 Bq, the effective dose would be 21.1 +/- 2.2 mSv for the 4.8-h interval, reduced to 8.3 +/- 1.1 mSv f

155 uced with protocol B (2.6 mSv +/- 0.4 vs 3.2 mSv +/- 0.8 with protocol A; P < .0041).

156 n exposure (6.1 +/- 0.4 mSv vs. 13.4 +/- 3.2 mSv; p < 0.001).

157 Effective doses varied from 0.03 to 69.2 mSv per scan.

158 or PET imaging, with a total dose of about 2 mSv for a brain PET/CT protocol.

159 o the nearby population of less than about 2 mSv, discernible impacts to the health of the exposed po

160 (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv

161 ions, respectively, were as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR

162 However, a protocol effective dose >20 mSv was proposed as a level requiring particular attenti

163 years was 682 mSv (tumors < 1.2 cm) and 2125 mSv (tumors > 3 cm).

164 is corresponded to an effective dose of 0.22 mSv and 0.1 mSv.

165 effective dose was estimated to be 0.1-0.22 mSv depending on the fluoroscopic pulse rate utilised du

166 Radiation dose averaged 2.22 mSv over all patients.

167 11 mSv (0.47-2.01 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for method B.

168 Sv); and abdomen, 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

169 08 (1.51-12.36) minutes and 2.15 (0.58-8.22) mSv, respectively.

170 dose ranged between 3.33-4.42 and 3.11-4.23 mSv, respectively.

171 transforaminal epidural injections was 0.24 mSv +/- 0.22, compared with 0.33 mSv +/- 0.10 for CT-gui

172 q (5.4 mCi) of (68)Ga-FAPI-46 (1.56 +/- 0.26 mSv from the PET tracer and 3.7 mSv from 1 low-dose CT s

173 Bq (5.4 mCi) of (68)Ga-FAPI-46 (1.56+/- 0.26 mSv from the PET tracer and 3.7 mSv from one low-dose CT

174 fective total body dose is 1.56 mSv +/- 0.26 mSv, in addition to approximately 3.7 mSv from one low-d

175 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

176 ion doses were highest for gallbladder (0.27 mSv/MBq), upper large intestine (0.19 mSv/MBq), and smal

177 dose for (124)I-omburtamab was 0.49 +/- 0.27 mSv/MBq.

178 t, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv (IQR, 6-18 mSv); and abdomen, 10 mSv (I

179 e was lower for the CCTA group (24 versus 29 mSv; P < 0.001).

180 ve dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

181 Mean effective dose was 4.3 +/- 0.3 mSv/patient (range, 3.7-4.9 mSv).

182 vely, were as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); ch

183 - 2.0 mGy, 148 +/- 85 mGycm, and 2.2 +/- 1.3 mSv) were significantly lower than for FBP CT (8.5 +/- 3

184 functional-testing group (10.0 mSv vs. 11.3 mSv), but 32.6% of the patients in the functional-testin

185 ), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 m

186 timated to have been 2.9 mSv in 2006 and 2.3 mSv in 2016, with the collective doses being 885 000 and

187 ased on 150 MBq of (68)Ga-pentixafor was 2.3 mSv.

188 y, through both CT and radiographs, was 24.3 mSv.

189 -DOTA-Siglec-9 would expose a subject to 3.3 mSv.

190 le, with an estimated whole-body dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga

191 ile with an estimated whole body dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga

192 pared with the transition group (4.2 +/- 5.3 mSv vs. 0.01 +/- 0.01 mSv, p = 0.036).

193 lower (a "reduced dose") (effective dose, 3 mSv), and only 10% of institutions kept DLP at 400 mGy c

194 radiation exposure in the United States is 3 mSv/y, and added exposures of less than 15 mSv are consi

195 An imaging protocol with effective dose </=3 mSv is considered very low risk, not warranting extensiv

196 mSv/MBq, leading to a radiation burden of 3 mSv when the clinical target dose of 200 MBq was used.

197 (0.46 x 10(-3) mSv +/- 0.93 vs 0.06 x 10(-3) mSv +/- 0.24, respectively; P < .006).

198 0.42 x 10(-3) mSv +/- 0.99 vs 0.11 x 10(-3) mSv +/- 0.44, P < .03; wrist: 1.44 x 10(-3) mSv +/- 2.69

199 1.44 x 10(-3) mSv +/- 2.69 vs 0.14 x 10(-3) mSv +/- 0.55, P < .001).

200 uided lumbar facet injections (0.46 x 10(-3) mSv +/- 0.93 vs 0.06 x 10(-3) mSv +/- 0.24, respectively

201 nal epidural injections (body: 0.42 x 10(-3) mSv +/- 0.99 vs 0.11 x 10(-3) mSv +/- 0.44, P < .03; wri

202 mSv +/- 0.44, P < .03; wrist: 1.44 x 10(-3) mSv +/- 2.69 vs 0.14 x 10(-3) mSv +/- 0.55, P < .001).

203 - 0.04 mSv for the 32-MDCT and 1.25 +/- 0.30 mSv for the 16-MDCT.

204 provided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the

205 0.52 mSv [95% CI confidence interval : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confide

206 e estimated effective dose was 2.32 +/- 0.32 mSv for an injected dose of 20 MBq in newborns.

207 , 10 mSv (IQR, 6-16 mSv), 22 mSv (IQR, 15-32 mSv), and 17 mSv (IQR, 11-26 mSv).

208 without HCC, 137 mSv (IQR: 87,259) versus 32 mSv (IQR: 13,57), respectively.

209 ns was 0.24 mSv +/- 0.22, compared with 0.33 mSv +/- 0.10 for CT-guided injections (P < .003).

210 ns was 0.10 mSv +/- 0.11, compared with 0.33 mSv +/- 0.13 for CT-guided injections (P < .001).

211 173 mGy x cm, 0.46 +/- 0.4 and 1.31 +/- 0.33 mSv for 16-MDCT and 64-MDCT, respectively.

212 ivered mean radiation doses of 5.56 and 3.33 mSv, respectively (P < .05).

213 ion for a mean effective dose of 0.97+/-0.34 mSv.

214 n chest radiation exposure (0.06 versus 0.34 mSv; P=0.037, Mann-Whitney U test) and lower median cost

215 ed doses were the urinary bladder wall (0.38 mSv/MBq) and kidneys (0.054 mSv/MBq).

216 0.001), and radiation exposure (6.1 +/- 0.4 mSv vs. 13.4 +/- 3.2 mSv; p < 0.001).

217 .6 +/- 8.7 mSv, in comparison to 3.6 +/- 1.4 mSv for PET/MRI, resulting in a potential dose reduction

218 3.7 mGy, 365 +/- 160 mGycm, and 5.5 +/- 2.4 mSv).

219 on doses were calculated to be 2.64 and 26.4 mSv for FPA and MSM techniques, respectively.

220 s to an equivalent dose of approximately 3-4 mSv.

221 ith current radiation exposures (median, 3.4 mSv), breast shielding yielded a 33% increase in image n

222 re as follows: head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 m

223 MBq, which would yield a radiation dose of 4 mSv to a patient after injection of 185 MBq of (68)Ga-NO

224 s than 1 mSv for 58 (54.2%), and less than 4 mSv for 103 (96.3%).

225 respectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

226 beled with (89)Zr (0.0124 mSv/MBq vs. 0.4162 mSv/MBq, respectively).

227 dard deviation] and 0.78 mSv +/- 0.2 vs 0.44 mSv +/- 0.1; P < .0001), respectively, for the 80- and 1

228 t significantly reduced radiation dose (0.44 mSv) and contrast medium volume (45 mL), thus enabling s

229 wer compared with standard CT (3.33 and 4.44 mSv, respectively).

230 verall, the radiation dose was less than 0.5 mSv for 23 of the 107 CT angiography examinations (21.5%

231 dose (0.5-5.0 mSv, with stepped doses of 0.5 mSv).

232 ) (9.8 +/- 2.1 mSv) and ED(MC) (11.6 +/- 1.5 mSv).

233 a total effective dose of approximately 1.5 mSv.

234 Mean exposure to ionising radiation was 12.5 mSv (SD 4.1) for (18)F-FDG PET/CT compared with zero for

235 ective dose equivalent of approximately 13.5 mSv, roughly equivalent to a clinical [(18)F]-FDG proced

236 ionizing radiation was estimated to be 14.5 mSv for one PET/CT examination versus 0.1 mSv for one ch

237 At 2.5 mSv, the maximum mean differences in values from those o

238 CT perfusion protocol can be lowered to 2.5 mSv, with only minor quantitative effects on perfusion v

239 of 307-1497 mGy cm (effective dose, 4.6-22.5 mSv) for mean DLPs.

240 ED(DLP) (13.2 +/- 4.5 mSv) was higher compared to ED(NCI) (9.8 +/- 2.1 mSv) an

241 proportion of healthy patients exposed to >5 mSv chest radiation.

242 The proportion with >5 mSv to the chest and no significant cardiopulmonary diag

243 r wall (0.62 mSv/MBq) and the pancreas (0.51 mSv/MBq).

244 Median annualized effective RE was 51 mSv (interquartile range [IQR]: 19,126), with 10% expose

245 han those with conventional CT (median: 0.52 mSv [95% CI confidence interval : 0.31 mSv, 3.90 mSv] fo

246 ure of 0.29 +/- 0.12 mSv (range 0.16 to 0.53 mSv), yielding 96.9% (436 of 450) interpretable segments

247 fective dose due to (124)I-BTT-1023 was 0.55 mSv/MBq, if blockage of thyroid uptake is assumed.

248 The mean effective radiation dose was 0.56 mSv +/- 0.25 (standard deviation).

249 API-46 the effective total body dose is 1.56 mSv +/- 0.26 mSv, in addition to approximately 3.7 mSv f

250 1.12 mSv [95% CI confidence interval : 0.57 mSv, 3.15 mSv] for adults) and of the same order of magn

251 r-patient was higher in DURING_Tl-201 (23.57 mSv; 95% confidence interval, 23.16-23.96) than in Tc-99

252 - 0.2 mSv, and for (68)Ga-FAPI-74 it was 1.6 mSv.

253 s significantly reduced with protocol B (2.6 mSv +/- 0.4 vs 3.2 mSv +/- 0.8 with protocol A; P < .004

254 racers such as somatostatin analogs (2.1-2.6 mSv/100 MBq) and are beneficial for application as a res

255 02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity of 150 MBq.

256 .043 mSv/MBq, resulting in an average of 4.6 mSv per patient.

257 of (68)Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD.

258 ns kept DLP at 400 mGy cm (effective dose, 6 mSv) or less in at least 50% of patients.

259 ed doses were the urinary bladder wall (0.62 mSv/MBq) and the pancreas (0.51 mSv/MBq).

260 stimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-MBq dose).

261 diation dose from age 40 to 65 years was 682 mSv (tumors < 1.2 cm) and 2125 mSv (tumors > 3 cm).

262 tion dose from CAC acquisition was 1.4+/-0.7 mSv.

263 all median cumulative effective dose was 2.7 mSv (range, 0.1-76.9 mSv), and the associated lifetime a

264 ation exposure (5.5 +/- 4.4 vs. 12.5 +/- 2.7 mSv, P < 0.0001).

265 .56 +/- 0.26 mSv from the PET tracer and 3.7 mSv from 1 low-dose CT scan).

266 - 0.26 mSv, in addition to approximately 3.7 mSv from one low-dose CT scan done for attenuation corre

267 1.56+/- 0.26 mSv from the PET tracer and 3.7 mSv from one low-dose CT scan).

268 nd the effective dose varied from 2.4 to 3.7 mSv.

269 se of 7.7 mSv, which could be reduced to 5.7 mSv with frequent bladder voids.

270 86-7548 results in an effective dose of 7.7 mSv, which could be reduced to 5.7 mSv with frequent bla

271 r whole-body PET/CT amounted to 17.6 +/- 8.7 mSv, in comparison to 3.6 +/- 1.4 mSv for PET/MRI, resul

272 200 MBq for (64)CuCl2 translated into a 5.7-mSv effective dose.

273 ference doses in the range from 820 to 1,700 mSv follow, a result which is consistent with biodosimet

274 92 mSv +/- 0.3 [standard deviation] and 0.78 mSv +/- 0.2 vs 0.44 mSv +/- 0.1; P < .0001), respectivel

275 head, 2 mSv (IQR, 1-3 mSv), 4 mSv (IQR, 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13

276 dian, 6.9 mSv; interquartile range, 3.8213.8 mSv; n = 6218) were similar to those of staff wearing tw

277 e island of Bikini (mean = 184 mrem/y = 1.84 mSv/y).

278 1 mSv) for method A and 8.22 mSv (2.19-12.88 mSv) for method B.

279 The median radiation dose with CCTA was 5.88 mSv (n = 1039; confidence interval: 5.2 to 6.4).

280 The mean effective dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

281 The mean patient dose was 2.7 +/- 0.9 mSv/patient.

282 al procedures was estimated to have been 2.9 mSv in 2006 and 2.3 mSv in 2016, with the collective dos

283 was 4.3 +/- 0.3 mSv/patient (range, 3.7-4.9 mSv).

284 esult in an effective dose equivalent of 5.9 mSv (0.59 rem) and a lung dose of 21.8 mGy (2.18 rad) in

285 The effective dose was estimated at 6.9 mSv for a 370-MBq (18)F-FTT dose in humans.

286 s for workers wearing one badge (median, 6.9 mSv; interquartile range, 3.8213.8 mSv; n = 6218) were s

287 effective dose was 2.7 mSv (range, 0.1-76.9 mSv), and the associated lifetime attributable risk of c

288 3-8 mSv), and 2 mSv (IQR, 2-3 mSv); chest, 9 mSv (IQR, 5-13 mSv), 18 mSv (IQR, 12-29 mSv), and 11 mSv

289 [95% CI confidence interval : 0.31 mSv, 3.90 mSv] for children and 1.12 mSv [95% CI confidence interv

290 ined indicated exposures between 600 and 900 mSv.

291 effective dose was 75% and 108% higher (0.92 mSv +/- 0.3 [standard deviation] and 0.78 mSv +/- 0.2 vs

292 interval, 23.16-23.96) than in Tc-99m (12.92 mSv; 95% confidence interval, 12.55-13.40; P<0.001).

293 mmitted effective dose of approximately 0.95 mSv a(-1) from combined FDNPP and ambient radionuclides,

294 e, including planning acquisitions, was 0.99 mSv (21% reduction) for patients (effective dose) and 0.

295 whom radiation effective dose averaged 0.99 mSv and study duration, 117 min.

296 The individual organ doses (mSv/MBq) were 0.40 +/- 0.058 for the urinary bladder wal

297 Radiation exposure is reported in mSv, a standardized measure of the detrimental biologic

298 adiation exposure measured in millisieverts (mSv) and medical charges for the respective diagnostic p

299 Mean dose values (mSv) reported from anterior parts of the phantom section

300 rem/year (mrem/y) = 0.076 millisievert/year (mSv/y)], larger levels of gamma radiation for the island